Veljković Andrej, Hadži-Dokić Jovan, Sokolović Dušan, Bašić Dragoslav, Veličković-Janković Ljubinka, Stojanović Marko, Popović Dejan, Kocić Gordana
Faculty of Medicine, University of Niš, 18 000 Niš, Serbia.
Serbian Academy of Sciences and Arts, 11 000 Belgrade, Serbia.
Diagnostics (Basel). 2020 Sep 3;10(9):668. doi: 10.3390/diagnostics10090668.
Prostate cancer (PC) is one of the most frequent malignancies. Better biomarkers are constantly wanted, such as those which can help with the prediction of cancer behavior. What is also needed is a marker which may serve as a possible therapeutic target. Oxidative stress (OS), which is a hallmark of cancer, is included in the pathogenesis and progression of PC. We have conducted the present study to determine whether xanthine oxidase/dehydrogenase activity is the source of OS in prostate tissue. We have also determined the concentration of TBA-reactive substances (TBARS) and advanced oxidation protein products (AOPP), as well as the activity of catalase. Xanthine oxidase (XO) activity is significantly higher ( < 0.001) in tumor tissue when compared to the control healthy tissue. The concentration of TBARS ( < 0.001) and AOPP ( < 0.05) are also higher in tumor tissue. Catalase has raised its activity ( < 0.05) versus the control. There is also a strong correlation between XO activity and prostate-specific antigen (PSA) levels in the serum. These results indicate a significant role of XO activity in OS in prostate carcinogenesis, and it could be a possible theranostic biomarker, which can be important for a better understanding of the disease, its evolution, and prognosis. A promising treatment may be using XO inhibitors such as allopurinol as adjuvant therapy.
前列腺癌(PC)是最常见的恶性肿瘤之一。人们一直需要更好的生物标志物,比如那些有助于预测癌症行为的标志物。还需要一种可能作为治疗靶点的标志物。氧化应激(OS)是癌症的一个标志,它参与了前列腺癌的发病机制和进展过程。我们开展了本研究,以确定黄嘌呤氧化酶/脱氢酶活性是否是前列腺组织中氧化应激的来源。我们还测定了硫代巴比妥酸反应性物质(TBARS)和晚期氧化蛋白产物(AOPP)的浓度,以及过氧化氢酶的活性。与对照健康组织相比,肿瘤组织中的黄嘌呤氧化酶(XO)活性显著更高(<0.001)。肿瘤组织中TBARS的浓度(<0.001)和AOPP的浓度(<0.05)也更高。过氧化氢酶的活性相对于对照有所升高(<0.05)。血清中XO活性与前列腺特异性抗原(PSA)水平之间也存在很强的相关性。这些结果表明XO活性在前列腺癌发生过程中的氧化应激中起重要作用,它可能是一种潜在的诊疗生物标志物,这对于更好地理解该疾病、其发展过程及预后可能具有重要意义。一种有前景的治疗方法可能是使用黄嘌呤氧化酶抑制剂,如别嘌醇作为辅助治疗。